Literature DB >> 1823625

Overexpression of the human melanoma-associated antigen ME491 partially suppresses in vivo malignant phenotypes of H-ras-transformed NIH3T3 cells in athymic nude mice.

H Hotta1, I Hara, H Miyamoto, M Homma.   

Abstract

H-ras-transformed NIH3T3 cells that overexpressed a human melanoma-associated antigen ME491 (44-3H) were generated by transfection with the cloned ME491 antigen gene followed by a 'panning' selection, and effects of the antigen overexpression on H-ras-mediated malignant phenotypes were studied. Although in vitro growth properties of the 44-3H overexpresser cells, both anchorage-dependent and -independent, were practically the same as those of the 44-1C control cells, 44-3H cells exhibited less malignant phenotypes in athymic nude mice (in vivo), i.e. decreased tumourigenicity after subcutaneous inoculation and prolonged survival time after intraperitoneal inoculation, compared with 44-1C cells. These results suggested that overexpression of ME491 antigen partially suppressed malignant phenotypes of H-ras-transformed NIH3T3 cells in athymic nude mice through co-operating with a factor(s) or mechanism(s) that exist in vivo but not in vitro. Thus, ME491 antigen might act as a tumour suppressor under some circumstances.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1823625     DOI: 10.1097/00008390-199106000-00007

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  2 in total

1.  CD63 tetraspanin is a negative driver of epithelial-to-mesenchymal transition in human melanoma cells.

Authors:  Antonella Lupia; Silvia Peppicelli; Ewa Witort; Francesca Bianchini; Vinicio Carloni; Nicola Pimpinelli; Carmelo Urso; Lorenzo Borgognoni; Sergio Capaccioli; Lido Calorini; Matteo Lulli
Journal:  J Invest Dermatol       Date:  2014-06-18       Impact factor: 8.551

2.  Protein kinase activity is associated with CD63 in melanoma cells.

Authors:  Joji Iida; Amy P N Skubitz; James B McCarthy; Keith M Skubitz
Journal:  J Transl Med       Date:  2005-11-30       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.